GT
ANTH

Glenmede Trust’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Glenmede Trust’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-375
Closed -$10K – 2805
2016
Q1 		$10K Hold
375
– – ﹤0.01% 2058
2015
Q4 		$13K Hold
375
– – ﹤0.01% 2000
2015
Q3 		$18K Buy
+375
New +$26.2K ﹤0.01% 1935

Other funds holding ANTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust's ANTH Position: Q2 2016 in Review

Glenmede Trust sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2016, closing a stake of 375 shares — an estimated $10K sold.

Glenmede Trust first reported a position in ANTH in Q3 2015 and held it in 3 quarters. The position peaked at $18K in Q3 2015. 74 funds tracked by Wall St. Rank hold ANTH as of Q2 2016.

  • Glenmede Trust reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Glenmede Trust sold 375 Anthera Pharmaceuticals, Inc. shares in Q2 2016, an estimated $10K.
  • Glenmede Trust first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
  • Glenmede Trust's Anthera Pharmaceuticals, Inc. position peaked at $18K in Q3 2015.
  • 74 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2016.

Based on Glenmede Trust's 13F filing for Q2 2016, filed 5 Aug 2016.